Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1625166

This article is part of the Research TopicInterdisciplinary Innovations in CAR T Cell Therapy for Autoimmune and Cancer TreatmentView all 3 articles

CAR-T Therapy: Pioneering a New Era in the Treatment of Autoimmune Diseases

Provisionally accepted
YuanHao WuYuanHao Wu1,2Luyao HanLuyao Han1,2Yu WangYu Wang1,2Mengjiao GuMengjiao Gu1,2Yunuo WangYunuo Wang1,2Jingyue GaoJingyue Gao1,2Hanjing HuangHanjing Huang1,2Chen LiChen Li3,4*
  • 1First teaching Hospital of Tianjin University of Traditional Chinese Medicience, Tianjin, China
  • 2National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China
  • 3Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China
  • 4Department of Rheumatology, Fangshan Hospital, Beijing University of Chinese Medicine, Beijing, China, Beijing, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

CAR-T therapy, an innovative immunotherapeutic approach, genetically modifies T cells to express CARs, enabling targeted destruction of specific antigen-expressing cells. Initially developed for oncology, CAR-T therapy has shown significant potential in treating autoimmune diseases. By targeting CD19+ B cells, CAR-T therapy has demonstrated rapid and sustained remission in refractory cases, with studies showing normalized laboratory parameters and reduced disease activity. However, some adverse effects also exist, including CRS, ICANS, and OTOT. Despite these challenges, CAR-T therapy represents a promising advancement in autoimmune disease treatment, with ongoing research aimed at enhancing efficacy, durability, and safety. Continuous innovation is essential to address limitations and optimize therapeutic outcomes.

Keywords: Chimeric antigen receptor T-cell therapy, CAR (chimeric antigen receptor), SLE - systemic lupus erthematosus, Autoimmune Diseases, Adverse (side) effects

Received: 08 May 2025; Accepted: 23 Jul 2025.

Copyright: © 2025 Wu, Han, Wang, Gu, Wang, Gao, Huang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Chen Li, Department of Dermatology, Tianjin Institute of Integrative Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material